Atlas Trials

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Clinical trial NCT03437083 · COMPLETED

Trial details

NCT number
NCT03437083
Sponsor
Eisai Korea Inc.
Status
COMPLETED
Study type
OBSERVATIONAL
Locally Advanced or Metastatic Breast Cancer
Start date
2018-01-25
Primary completion
2018-06-30
Enrollment
340

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.